NCT05372016View on ClinicalTrials.gov

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

PHASE3CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

September 19, 2020

Primary Completion Date

June 17, 2022

Study Completion Date

June 17, 2022

Conditions
HPV InfectionsCervical CancerVulvar CancerVaginal CancerCIN1CIN2CIN3VaIN1VaIN2VaIN3Genital WartVIN 1VIN 2VIN 3AIS
Interventions
BIOLOGICAL

Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)

9vHPV vaccine ,0.5mL, three doses, 0,2,6 months

BIOLOGICAL

Active Comparator: GARDASIL ®9

GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months

Trial Locations (1)

Unknown

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Guangxi

All Listed Sponsors
collaborator

Chongqing Bovax Biopharmaceutical Co., Ltd.

INDUSTRY

lead

Shanghai Bovax Biotechnology Co., Ltd.

INDUSTRY

NCT05372016 - Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | Biotech Hunter | Biotech Hunter